Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

This study has been completed.
Sponsor:
Collaborator:
Eisai Inc.
Information provided by:
Astex Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00041990
First received: July 19, 2002
Last updated: December 12, 2007
Last verified: December 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given